FDA approves first gene therapy for haemophilia B
Drug Discovery World
NOVEMBER 24, 2022
The drug is approved for the treatment of adults with haemophilia B who currently use factor IX prophylaxis therapy, or have current or historical life-threatening haemorrhage or have repeated, serious spontaneous bleeding episodes. . A unique approach. at 24 months post infusion.
Let's personalize your content